Skip to main content
. 2021 May 22;394(8):1713–1725. doi: 10.1007/s00210-021-02100-7

Fig. 1.

Fig. 1

HMG-CoA-Reductase inhibitors (HMGRIs; formerly known as statins) lead to reduced FPP levels, which is the reason for reduced cholesterol synthesis and the rationale for their use in the prevention of coronary heart disease (CHD). Additionally, HMGRIs exhibit pleiotropic (i.e., cholesterol synthesis independent) effects, some of which may counteract their desired LDL-cholesterol lowering effect. Red arrows indicate up- and downregulation upon HMGRI treatment